12:00 AM
 | 
May 08, 2000
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Cell Pathways preclinical data

CLPA said that in rats, Aptosyn gave 61 percent inhibition of bladder tumor formation compared to controls. Separately, CLPA said that in...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >